HSDT, formerly Helius Medical Technologies, now holds 2.2 million SOL worth about $525 million and $15 million in cash. The move revives discussion about listed companies buying Solana and pushes treasurers, traders and risk teams to monitor exposure to the token.
The company’s treasury position aligns with a growing focus on digital assets in corporate finance, with HSDT confirming its SOL and cash balances. Staking — where token holders lock coins to help secure the network and receive yield — is part of the broader context for how firms may manage SOL positions.
Share prices jumped after disclosures, with HSDT rising almost 190% once its filing became public. The announcement has forced finance teams to track balance-sheet sensitivity to SOL price swings as listed buyers weigh treasury diversification.
Wider pattern and potential outcomes
Around eighteen Nasdaq firms now own more than $4 billion in SOL, per sector data cited. Forward Industries reports 6.8 million SOL (roughly $1.69 billion) and Upexi holds about 2 million SOL (around $377 million), while other issuers run programs mixing direct buys, private deals and placements to raise SOL; additional names include VisionSys AI in specialized press.
Listed buyers treat SOL as a balance sheet item and draw more capital. Large bids lift demand and shrink the free float, while earnings grow more sensitive to SOL price swings.
Mark-to-market moves feed straight into equity and profit; the treasury gains or loses with each price tick. A U.S. spot SOL ETF and the draft CLARITY Act could open doors for institutional funds.
HSDT at 2.2 million SOL (≈$525 million) plus $15 million cash; combined disclosed holdings near $4 billion across eighteen firms; and a roster that includes Forward Industries, Upexi and VisionSys AI.
Next watchpoints center on further corporate filings and regulatory news. HSDT announced its position on 6 October, and analysts cite a potential spot SOL ETF decision or progress on the CLARITY Act as likely catalysts.
In sum, corporate stockpiling of SOL is moving from headline to balance sheet, with price sensitivity, liquidity effects and regulatory milestones set to shape how far listed firms go in adopting Solana as a treasury asset.
